Eloxx Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Eloxx Pharmaceuticals

03/04/2023 23:31

* Eloxx Pharmaceuticals Inc  ELOX.OQ  reported a quarterly
adjusted loss of $2.92​​ per share for the quarter ended in
December. The lone analyst forecast for the quarter was for a
loss of $2.97 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Eloxx Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $2.92​.
    * The mean earnings estimate of analysts had risen by
about 32.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Eloxx Pharmaceuticals Inc shares had held steady so far
this
quarter and gained 37.9% so far this year.
    * The company reported a quarterly loss of $6.32 million.
    * Wall Street's median 12-month price target for Eloxx
Pharmaceuticals Inc is $50.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
April 3 at 10:30 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -2.97          -2.92          Beat
 Sep. 30 2022      -4.40          -3.60          Beat
 Jun. 30 2022      -4.13          -4.80          Missed
 Mar. 31 2022      -3.70          -5.20          Missed